These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 12649150)

  • 1. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation.
    Wells DA; Benesch M; Loken MR; Vallejo C; Myerson D; Leisenring WM; Deeg HJ
    Blood; 2003 Jul; 102(1):394-403. PubMed ID: 12649150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
    Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
    Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome.
    Scott BL; Wells DA; Loken MR; Myerson D; Leisenring WM; Deeg HJ
    Blood; 2008 Oct; 112(7):2681-6. PubMed ID: 18606877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes.
    Chu SC; Wang TF; Li CC; Kao RH; Li DK; Su YC; Wells DA; Loken MR
    Leuk Res; 2011 Jul; 35(7):868-73. PubMed ID: 21397943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
    Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system.
    Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
    Leukemia; 2016 Mar; 30(3):658-65. PubMed ID: 26503643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy.
    Gauthier J; Damaj G; Langlois C; Robin M; Michallet M; Chevallier P; Beguin Y; N'guyen S; Bories P; Blaise D; Cornillon J; Clavert A; Mohty M; Huynh A; Thiébaut-Bertrand A; Vigouroux S; Duhamel A; Yakoub-Agha I
    Transplantation; 2015 Aug; 99(8):1672-80. PubMed ID: 25769079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of multiparameter flow cytometry in the diagnosis and prognostic evaluation of childhood myelodysplastic syndrome].
    Liu C; An WB; Zhang JL; Zhang RR; Sun CC; Chang LX; Liu TF; Zou Y; Wang HJ; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2018 Oct; 20(10):819-824. PubMed ID: 30369356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometry in myelodysplastic syndrome: analysis of diagnostic utility using maturation pattern-based and quantitative approaches.
    Chopra A; Pati H; Mahapatra M; Mishra P; Seth T; Kumar S; Singh S; Pandey S; Kumar R
    Ann Hematol; 2012 Sep; 91(9):1351-62. PubMed ID: 22526362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome.
    Stetler-Stevenson M; Arthur DC; Jabbour N; Xie XY; Molldrem J; Barrett AJ; Venzon D; Rick ME
    Blood; 2001 Aug; 98(4):979-87. PubMed ID: 11493442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome.
    Ustun C; Trottier BJ; Sachs Z; DeFor TE; Shune L; Courville EL; Holtan SG; Dolan M; Weisdorf DJ; Warlick ED
    Biol Blood Marrow Transplant; 2015 May; 21(5):866-72. PubMed ID: 25620751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
    Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
    Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.
    Deeg HJ; Scott BL; Fang M; Shulman HM; Gyurkocza B; Myerson D; Pagel JM; Platzbecker U; Ramakrishnan A; Radich JP; Sandmaier BM; Sorror M; Stirewalt DL; Wilson WA; Storb R; Appelbaum FR; Gooley T
    Blood; 2012 Aug; 120(7):1398-408. PubMed ID: 22767498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow-cytometric analysis of peripheral blood neutrophils: a simple, objective, independent and potentially clinically useful assay to facilitate the diagnosis of myelodysplastic syndromes.
    Cherian S; Moore J; Bantly A; Vergilio JA; Klein P; Luger S; Bagg A
    Am J Hematol; 2005 Jul; 79(3):243-5. PubMed ID: 15981222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
    Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Abnormalities of CD34+ cells differentiation and bone marrow cell cycle in myelodysplastic syndrome].
    Li LJ; Fu R; Shao ZH; Wang HQ; Yue LZ; Ruan EB; Liu H; Wang J; Wang HL
    Zhonghua Nei Ke Za Zhi; 2010 Nov; 49(11):963-6. PubMed ID: 21211213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The prognostic significance of pretransplantation evaluation of IPSS-R and WPSS in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation].
    Lu CQ; Hou C; Wang P; Zhang LW; Fan Y; Wu DP; Xu Y
    Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):247-254. PubMed ID: 35405784
    [No Abstract]   [Full Text] [Related]  

  • 18. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score.
    Appelbaum FR; Anderson J
    Leukemia; 1998 Sep; 12 Suppl 1():S25-9. PubMed ID: 9777891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research advances in value of flow cytometric immunophenotyping in diagnosis and prognostic evaluation of myelodysplastic syndrome].
    Lu D; Liu YR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):785-90. PubMed ID: 23815941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
    Kao JM; McMillan A; Greenberg PL
    Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.